Next Article in Journal
Functional Characterization of PsnNAC036 under Salinity and High Temperature Stresses
Next Article in Special Issue
Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia
Previous Article in Journal
Antimetastatic and Antitumor Activities of Orally Administered NAX014 Compound in a Murine Model of HER2-Positive Breast Cancer
Previous Article in Special Issue
Insights into Bioinformatic Applications for Glycosylation: Instigating an Awakening towards Applying Glycoinformatic Resources for Cancer Diagnosis and Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 5
10.3390/ijms22052655
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer

by
Randa G. Hanna-Sawires
1,
Jorinde H. Schiphuis
1,
Manfred Wuhrer
2,
Hans F. A. Vasen
3,
Monique E. van Leerdam
3,
Bert A. Bonsing
1,
Wilma E. Mesker
1,
Yuri E. M. van der Burgt
2,* and
Rob A. E. M. Tollenaar
1
1
Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
2
Center of Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
3
Department of Gastroenterology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(5), 2655; https://doi.org/10.3390/ijms22052655
Submission received: 27 January 2021 / Revised: 26 February 2021 / Accepted: 2 March 2021 / Published: 6 March 2021
(This article belongs to the Special Issue Recent Advances of Proteomics Applied to Cancer and Human Diseases)
Browse Figures
Versions Notes

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is known as a highly aggressive malignant disease. Prognosis for patients is notoriously poor, despite improvements in surgical techniques and new (neo)adjuvant chemotherapy regimens. Early detection of PDAC may increase the overall survival. It is furthermore foreseen that precision medicine will provide improved prognostic stratification and prediction of therapeutic response. In this review, omics-based discovery efforts are presented that aim for novel diagnostic and prognostic biomarkers of PDAC. For this purpose, we systematically evaluated the literature published between 1999 and 2020 with a focus on protein- and protein-glycosylation biomarkers in pancreatic cancer patients. Besides genomic and transcriptomic approaches, mass spectrometry (MS)-based proteomics and glycomics of blood- and tissue-derived samples from PDAC patients have yielded new candidates with biomarker potential. However, for reasons discussed in this review, the validation and clinical translation of these candidate markers has not been successful. Consequently, there has been a change of mindset from initial efforts to identify new unimarkers into the current hypothesis that a combination of biomarkers better suits a diagnostic or prognostic panel. With continuing development of current research methods and available techniques combined with careful study designs, new biomarkers could contribute to improved detection, prognosis, and prediction of pancreatic cancer.
Keywords: pancreatic cancer; biomarker; mass spectrometry; proteomics; glycomics; glycosylation; early detection; prediction; prognosis; CA 19-9 pancreatic cancer; biomarker; mass spectrometry; proteomics; glycomics; glycosylation; early detection; prediction; prognosis; CA 19-9

Share and Cite

MDPI and ACS Style

Hanna-Sawires, R.G.; Schiphuis, J.H.; Wuhrer, M.; Vasen, H.F.A.; van Leerdam, M.E.; Bonsing, B.A.; Mesker, W.E.; van der Burgt, Y.E.M.; Tollenaar, R.A.E.M. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. Int. J. Mol. Sci. 2021, 22, 2655. https://doi.org/10.3390/ijms22052655

AMA Style

Hanna-Sawires RG, Schiphuis JH, Wuhrer M, Vasen HFA, van Leerdam ME, Bonsing BA, Mesker WE, van der Burgt YEM, Tollenaar RAEM. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. International Journal of Molecular Sciences. 2021; 22(5):2655. https://doi.org/10.3390/ijms22052655

Chicago/Turabian Style

Hanna-Sawires, Randa G., Jorinde H. Schiphuis, Manfred Wuhrer, Hans F. A. Vasen, Monique E. van Leerdam, Bert A. Bonsing, Wilma E. Mesker, Yuri E. M. van der Burgt, and Rob A. E. M. Tollenaar. 2021. "Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer" International Journal of Molecular Sciences 22, no. 5: 2655. https://doi.org/10.3390/ijms22052655

APA Style

Hanna-Sawires, R. G., Schiphuis, J. H., Wuhrer, M., Vasen, H. F. A., van Leerdam, M. E., Bonsing, B. A., Mesker, W. E., van der Burgt, Y. E. M., & Tollenaar, R. A. E. M. (2021). Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. International Journal of Molecular Sciences, 22(5), 2655. https://doi.org/10.3390/ijms22052655

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop